Loading
Embecta Corp. Stock: price and insider trades · United States
4 insiders bought €483k of shares over the last 90 days, the latest filed 13 Aug 2026.
Embecta Corp.: what insiders have been doing
Embecta Corp. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Embecta Corp. logged 19 filings by 13 insiders.
Open-market activity splits into 4 purchases totalling €483k and 1 sale totalling €32k; 4 insiders sit on the buying side and 1 insider on the selling side. Purchases outweigh sales by €452k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 2 chief executives, 1 finance chief and 1 senior executive. At €194k, the purchase published on 13 August 2026 by Hombach Robert J. is the largest of the period (0.070% of market cap).
Compared with its exchange (5,814 companies, median 19 filings), a count of 19 filings is typical. The full history, which starts in 2022, counts 13 purchases against 1 sale. For the fiscal year to 30 September 2025, the annual 10-K puts revenue at 1.08 bn USD and net income at 95.4 m USD, and the dividend at 0.60 USD per share.
Within a 30-day window, 4 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 66 days ago, on 13 August 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
106
Thresholds
n/a
Buy Volume
€1M
13 ops. · all time
Sell Volume
€31,814
1 ops. · all time
Who traded when
BuySaleDavid F. Melcher2 buys
Devdatt Kurdikar1 buy
Jacob Elguicze1 buy
Jeffrey Z. Mann1 buy
Milton Mayo Morris1 sale
Robert J. Hombach1 buy
Since the insiders bought
- +2.7%Entry US$5.10 · Close at T+30 US$5.24
- +2.7%Entry US$5.10 · Close at T+30 US$5.24
- +2.7%Entry US$5.10 · Close at T+30 US$5.24
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Embecta Corp. Hold (neutral), based on 2 analysts. Average price target: US$4.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,278 of 24,158 companies
74.4
score / 100
Value93
Quality56
FCF yld51%
Earn yld27%
EV/EBITDA6.3x
ROE·
Gross mgn63%
Net mgn8.8%
Debt/EBITDA5.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
US$6.18
Analyst consensus
2 analystsHold
US$3.00Target US$4.00(-35%)US$5.00
Income statement
RevenueUS$1.1B
Gross profitUS$676.8M63% margin
EBITDAUS$284.3M26% margin
Net incomeUS$95.4M8.6% margin
Valuation
PER (trailing)4.2x
PER (forward)3.5x
Beta0.83
Balance sheet & cash
Market capUS$350.2M
Total debtUS$1.4B
Free Cash FlowUS$182.4M
Profitability & ownership
ROA12.2%
% insiders2.0%
% institutions91.5%
Last declaration on 8 September 2026
Declarations106 total
6,293 shares@ US$5.8750.011% mcap50.1% of flowCommon StockSEC:0000947871-26-000859:0
6,293 shares@ US$5.86220.011% mcap49.9% of flowCOMMONSEC144:0001000275-26-000105
20,000 shares@ US$4.6680.029% mcap30.4% of flowCommon StockSEC:0000947871-26-000788:0
Canonical exit: 10 Nov 2026 (T+90)
20,000 shares@ US$4.990.031% mcap36.5% of flowCommon StockSEC:0000947871-26-000787:0
Canonical exit: 10 Nov 2026 (T+90)
30,000 shares@ US$4.69790.044% mcap9.7% of flowCommon StockSEC:0000947871-26-000789:0
Canonical exit: 10 Nov 2026 (T+90)
45,000 shares@ US$4.97440.070% mcap100.0% of flowCommon StockSEC:0000947871-26-000786:0
Canonical exit: 10 Nov 2026 (T+90)
1,480 shares@ US$4.420.0020% mcap20.1% of flowCommon StockSEC:0000947871-26-000779:0
22,841 shares0Common StockSEC:0000947871-26-000165:0
22,841 shares0Common StockSEC:0000947871-26-000164:0
22,841 shares0Common StockSEC:0000947871-26-000163:0
22,841 shares0Common StockSEC:0000947871-26-000162:0
22,841 shares0Common StockSEC:0000947871-26-000161:0
22,841 shares0Common StockSEC:0000947871-26-000160:0
38,783 shares0Common StockSEC:0000947871-25-001052:0
79,555 shares0Common StockSEC:0000947871-25-001051:0
288,386 shares0Common StockSEC:0000947871-25-001050:0
95,466 shares0Common StockSEC:0000947871-25-001049:0
37,789 shares0Common StockSEC:0000947871-25-001048:0
32,817 shares0Common StockSEC:0000947871-25-001053:0
916 shares@ US$12.2834.2% of flowCommon StockSEC:0000947871-25-000735:0
10,000 shares@ US$10.599516.3% of flowCommon StockSEC:0000947871-25-000561:0
Canonical exit: 21 Aug 2025 (T+90)
39,592 shares@ US$12.0034.3% of flowCommon StockSEC:0000947871-25-000367:0
5,285 shares@ US$12.0024.3% of flowCommon StockSEC:0000947871-25-000368:0
3,249 shares@ US$12.0060.4% of flowCommon StockSEC:0000947871-25-000369:0
4,948 shares@ US$12.0020.2% of flowCommon StockSEC:0000947871-25-000370:0
25 of 106 declarations
About Embecta Corp.
Embecta Corp. is a company focused on the healthcare and pharmaceutical sector, specializing in diabetes management solutions. It is listed on NASDAQ under the ticker EMBecta.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
